← Back to Clinical Trials
Recruiting NCT05321992

NCT05321992 Evaluating a Community-Based Behaviour Change Communication Model to Prevent Cholangiocarcinoma in Khon Kaen, Thailand

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05321992
Status Recruiting
Phase
Sponsor McMaster University
Condition Cholangiocarcinoma
Study Type INTERVENTIONAL
Enrollment 480 participants
Start Date 2024-06-05
Primary Completion 2026-04-01

Eligibility & Interventions

Sex All sexes
Min Age 20 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
eCHEC program

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 480 participants in total. It began in 2024-06-05 with a primary completion date of 2026-04-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Liver cancer, specifically cholangiocarcinoma (CCA), is very common in different areas in Thailand. Many factors make this cancer more common, such as liver fluke infection, older age, eating raw fish, family history of cancer, alcohol intake, taking certain medicines (praziquantel), low intake of fresh vegetable, and low education. In 2015, researchers from Khon Kaen University developed the Community-based Health Education and Communication (CHEC) program to prevent liver cancer caused by liver flukes in communities of the Khon Kaen province, Thailand. The main aim of this 5-year research study is to enhance the CHEC program to prevent liver cancer, and test if it is effective in improving the knowledge and behaviours of community residents regarding how to prevent liver cancer. This study will take place in Khon Kaen, Thailand. Other aims are to: 1. Increase understanding in the community that make it difficult to prevent liver cancer, as well as community characteristics that can help prevent liver cancer; 2. Incorporate the program we develop in healthcare to prevent liver cancer in Thailand.

Eligibility Criteria

Inclusion Criteria: * any individual residing in one of the 16 villages selected in the Khon Kaen province of Thailand, aged 20 and older Exclusion Criteria: * any individual 19 years or younger * any individual not residing in one of the 16 pre-selected villages in the Khon Kaen province of Thailand

Contact & Investigator

Central Contact

Ricardo Angeles, MD, MPH, MHPEd, PhD

✉ angelesric@gmail.com

📞 905-515-2100

Principal Investigator

Gina Agarwal, MBBS, PhD

PRINCIPAL INVESTIGATOR

McMaster University

Frequently Asked Questions

Who can join the NCT05321992 clinical trial?

This trial is open to participants of all sexes, aged 20 Years or older, studying Cholangiocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05321992 currently recruiting?

Yes, NCT05321992 is actively recruiting participants. Contact the research team at angelesric@gmail.com for enrollment information.

Where is the NCT05321992 trial being conducted?

This trial is being conducted at Phu Wiang, Thailand.

Who is sponsoring the NCT05321992 clinical trial?

NCT05321992 is sponsored by McMaster University. The principal investigator is Gina Agarwal, MBBS, PhD at McMaster University. The trial plans to enroll 480 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology